Stereotactic Radiotherapy for the Management of Refractory Ventricular Tachycardia: Promise and Future Directions

Ventricular tachycardia (VT) caused by myocardial scaring bears a significant risk of mortality and morbidity. Antiarrhythmic drug therapy (AAD) and catheter ablation remain the cornerstone of VT management, but both treatments have limited efficacy and potential adverse effects. Stereotactic body r...

Descripción completa

Detalles Bibliográficos
Autores principales: Jumeau, Raphael, Ozsahin, Mahmut, Schwitter, Juerg, Elicin, Olgun, Reichlin, Tobias, Roten, Laurent, Andratschke, Nicolaus, Mayinger, Michael, Saguner, Ardan M., Steffel, Jan, Blanck, Oliver, Vozenin, Marie-Catherine, Moeckli, Raphael, Zeverino, Michele, Vallet, Véronique, Herrera-Siklody, Claudia, Pascale, Patrizio, Bourhis, Jean, Pruvot, Etienne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7329991/
https://www.ncbi.nlm.nih.gov/pubmed/32671101
http://dx.doi.org/10.3389/fcvm.2020.00108
Descripción
Sumario:Ventricular tachycardia (VT) caused by myocardial scaring bears a significant risk of mortality and morbidity. Antiarrhythmic drug therapy (AAD) and catheter ablation remain the cornerstone of VT management, but both treatments have limited efficacy and potential adverse effects. Stereotactic body radiotherapy (SBRT) is routinely used in oncology to treat non-invasively solid tumors with high precision and efficacy. Recently, this technology has been evaluated for the treatment of VT. This review presents the basic underlying principles, proof of concept, and main results of trials and case series that used SBRT for the treatment of VT refractory to AAD and catheter ablation.

Ejemplares similares